Stevanato group delivers double-digit revenue growth in fiscal year 2023

Piombino dese, italy--(business wire)--stevanato group s.p.a. (nyse: stvn), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2023. fourth quarter and fy 2023 highlights (compared with the same period last year) revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represente.
STVN Ratings Summary
STVN Quant Ranking